Insider buying last 90 days
No open-market insider purchases were filed for BHC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every BHC insider filing, plotted on the chart in Gekko.Open BHC in Gekko
NYSE: BHC
Bausch Health Companies (BHC) Stock Analysis & Forecast
Oct 12 close
$5.93−0.11 (−1.8%)
Gekko Brief
AI summaryOct 12 closeThis week's news centers on a leadership change at affiliate Bausch + Lomb, where Thomas J. Appio, who remains CEO of Bausch Health, has been named interim CEO following Brent Saunders' departure. Bausch + Lomb and Bausch Health jointly announced the move alongside an expectation to raise full-year 2026 guidance, while Bausch + Lomb shares fell nearly 10% on the leadership news. Separately, a Myositis pipeline report lists Bausch Health among more than 40 companies developing treatments in that space, and recent coverage notes Q2 FY26 revenue of $2.85 billion and earnings of $258 million, alongside an analyst average target price of $7.50.
BHC closed at $5.93, down 1.8%, sitting between its 50-day average of $6.19 and 200-day average of $5.75. The GekkoIndex reads 58.1, placing the stock in the Neutral zone, down 2.1 over five days. Gekko Fair Value stands at $9.73, putting the current price 39.1% below that level.
Earnings are scheduled for 28 October 2026, 16 days away, falling inside a typical 20-trading-day holding window; the prior quarter's report produced a 0.9% reaction with an average absolute reaction of 7.3% across recent quarters. No insider, Congress, or unusual options activity appears in the current windows. Seasonality from this point in the calendar has averaged a 6.8% move over the next 20 trading days across 5 years, rising in 4 of them, a pattern worth noting alongside the approaching report.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Bausch Health Companies price vs fair value
Close $5.93200-day averageGekko Fair Value $9.73
Bausch Health Companies quick facts
- Market cap
- $2.22B
- P/E ratio
- —
- Forward P/E
- 1.3
- EPS, TTM
- −$2.95
- Revenue, TTM
- $10.85B
- Profit margin
- -10.1%
- Dividend yield
- —
- Beta
- 0.37
- Volume
- 2.54M avg 1.82M
- 1-year return
- −7.2%
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±10.2%
- 50-day average
- $6.19
- 200-day average
- $5.75
- Next earnings
- Oct 28
- Shares outstanding
- 374.0M
Bausch Health Companies swing-trade checklist
Bausch Health Companies scores 2 supportive, 2 mixed and 1 headwind across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
2 supportive2 mixed1 headwind
- Trendmixed
Averages disagree
Close $5.93 sits between the 50-day ($6.19) and 200-day ($5.75) averages, or the averages disagree.
See the chart - GekkoIndexmixed
58.1, Neutral
Reading 58.1 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
39.1% below
Price is 39.1% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings riskheadwind
Reports in 16 days
Reports on Oct 28, 2026, 16 days away — inside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+6.8% on average
From this point in the calendar, the next 20 trading days averaged +6.8% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Bausch Health Companies stock chart and price history
Bausch Health Companies closed at $5.93 on Oct 12, 2026, −7.2% over the past year, inside a 52-week range of $4.33 to $8.00.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +1.2%
- 3 months
- +24.8%
- 6 months
- +3.7%
- 1 year
- −7.2%
The full BHC chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open BHC in Gekko
Follow Bausch Health Companies through every session
Put BHC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track BHC in GekkoFree for 7 days. No credit card required.
About Bausch Health Companies
Bausch Health Companies makes and sells pharmaceutical products, medical devices, and over-the-counter remedies, with particular attention to eye care, digestive conditions, and skin treatments. Its most recognized line comes from Bausch + Lomb, which covers surgical tools, consumer eye care items, and prescription eye medicines.
The business runs through five divisions. Beyond Bausch + Lomb, there is Salix, which handles gastroenterology products sold only in the United States, and International Rx, which brings branded and generic drugs, OTC goods, devices, and Solta-branded items to markets spanning Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics covers skin-related products domestically and also distributes Solta's aesthetic devices worldwide, while the Diversified Products unit sells neurology treatments, other therapeutic drugs, generics, and dental products, all within the U.S.
The company previously operated under the name Valeant Pharmaceuticals International, adopting its current name in July 2018. It is headquartered in Laval, Canada, and its shares trade on the NYSE under the ticker BHC.
- Listed
- NYSE
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Website
- bauschhealth.com
Bausch Health Companies GekkoIndex: the smart money zone
Bausch Health Companies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.1, in the Neutral zone, down 2.1 points over five sessions.
58.1Neutral
Down 2.1 points over five sessions, from the Accumulation zone.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 69 | −0.7% | +0.5% | ||
| Accumulation | 269 | +0.8% | +4.2% | ||
| Neutral (current zone) | 283 | −0.3% | −2.6% | ||
| Distribution | 54 | +0.3% | −2.9% | ||
| Selling | 7 | Too few readings yet | |||
Average BHC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the BHC price, zone by zone.Track BHC in Gekko
Is Bausch Health Companies stock overvalued? Gekko Fair Value
Bausch Health Companies trades 39.1% below Gekko Fair Value of $9.73, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Bausch Health Companies shares are worth, recalculated every trading day.
$9.73
Gekko Fair Value, Oct 10, 2026
39.1% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open BHC in Gekko
Bausch Health Companies insider and Congress trading
No open-market insider purchases were filed for Bausch Health Companies, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in BHC were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for BHC, plotted on the chart in Gekko.Open BHC in Gekko
Buybacks
Bausch Health Companies has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2025
- $3.00M
- As a share of market cap
- 0.14%
From company filings.
Hedge funds and billionaires quarter ended Mar 31
0of the funds Gekko tracks hold BHC.
0added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Bausch Health Companies earnings: next date and track record
Bausch Health Companies reports on Oct 28, 2026 (16 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Oct 28, 2026
16 days away
- EPS estimate
- $1.25
- Revenue estimate
- $2.72B
4 of 8reports beat the EPS estimate
±7.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Apr 29, 2026 AI summary
- What they said
- Bausch Health reported Q1 2026 revenue growth of 14% year-over-year (excluding Bausch & Lomb), marking 12 consecutive quarters of growth. Adjusted EBITDA increased 17%, driven by Salix (Xifaxan in IBS-D and OHE) and Solta's double-digit growth. Net debt was reduced by over $100 million, and U.S. opt-out litigation settlements concluded. Larsucosterol Phase III program for alcohol-associated hepatitis is advancing.
- Guidance
- Management confirmed cash flow generation is progressing toward guidance expectations. Capital allocation priorities focus on continued delevering and strategic business development investments. No updated revenue or EPS targets were provided in this excerpt.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 29, 2026 | $0.78 est $0.69 | $2.47B est $2.37B | +0.9% |
| Feb 18, 2026 | $1.08 est $1.21 | $2.79B est $2.73B | −1.0% |
| Oct 29, 2025 | $1.16 est $1.07 | $2.68B est $2.71B | +6.8% |
| Jul 30, 2025 | $0.90 est $0.97 | $2.53B est $2.58B | −13.6% |
| Apr 30, 2025 | $0.59 est $0.83 | $2.26B est $2.48B | −3.8% |
| Feb 19, 2025 | $1.16 est $1.13 | $2.56B est $2.29B | +12.9% |
| Oct 30, 2024 | $1.13 est $1.02 | $2.51B est $2.52B | +12.7% |
| Aug 1, 2024 | $0.03 est $0.88 | $2.40B est $2.34B | −6.6% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Bausch Health Companies stock forecast and analyst price targets
Analysts’ average 12-month price target for Bausch Health Companies is $7.50, +26.5% from the last close.
$7.50consensus 12-month target, +26.5% from the last close
−2.6%average 20-day move after past Neutral readings
+6.8%average move over the next 20 trading days in the last 5 years
±4.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Bausch Health Companies seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Bausch Health Companies averaged +6.8% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.9% | 3 of 5 |
| Next 10 trading days | −0.1% | 3 of 5 |
| Next 15 trading days | +1.1% | 3 of 5 |
| Next 20 trading days | +6.8% | 4 of 5 |
| Next 30 trading days | −2.7% | 2 of 5 |
For scale, BHC’s typical 20-trading-day move in either direction is about 10.2%.
Bausch Health Companies market cap and key statistics
Bausch Health Companies’s market cap is $2.22B and revenue of $10.85B over the last twelve months.
Valuation
- Market cap
- $2.22B
- Forward P/E
- 1.3
- EPS, TTM
- −$2.95
- Gekko Fair Value
- $9.73
Trading
- Volume
- 2.54M
- Avg volume, 20 days
- 1.82M
- 52-week high
- $8.00
- 52-week low
- $4.33
- Shares outstanding
- 374.0M
Financials
- Revenue, TTM
- $10.85B
- Profit margin
- -10.1%
- Return on equity
- 43.6%
- Quarterly earnings growth, YoY
- +70.4%
Risk and income
- Beta
- 0.37
- Typical daily move
- ±4.2%
- Typical 20-day move
- ±10.2%
Bausch Health Companies stock news this week
Coverage of Bausch Health Companies this week reads positive: 7 positive, 3 neutral and 1 negative headlines.
- Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders DepartsVisionMonday.com, Oct 12
- Why Is Bausch + Lomb Stock Falling Monday?Benzinga, Oct 12
- Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 GuidanceYahoo Finance, Oct 12
- Bausch Health Cos (NYSE:BHC) Shares Gap Up – What’s Next?Defense World, Oct 12
- Bausch + Lomb names Appio interim CEO as Saunders departsStreetInsider, Oct 12
- Myositis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Roche, Pfizer, Zydus Group, Lupin, Bausch Health, Accord Healthcare, GenentechStreetInsider, Oct 12
Bausch Health Companies peers
Bausch Health Companies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| RVMDRevolution Medicines | Accumulation | 6.4% below |
| CRONCronos Group Inc. Common | Neutral | 9.9% above |
| BRBRBellRing Brands | Accumulation | 45.8% below |
| AVBPArriVent BioPharma | Buying | 38.7% below |
| USNAUSANA Health Sciences | Neutral | 42.9% below |
| NATRNature's Sunshine Products | Accumulation | 43.9% below |
A peer links to its own page where one exists.
Bausch Health Companies stock FAQ
What is Bausch Health Companies’s market cap?
Bausch Health Companies’s market cap is $2.22B at the Oct 12, 2026 close of $5.93, with 374.0M shares outstanding.
What is the Bausch Health Companies stock forecast?
The consensus analyst 12-month price target for Bausch Health Companies is $7.50, +26.5% from the last close. Gekko doesn’t publish price predictions of its own.
Is Bausch Health Companies stock overvalued or undervalued?
On Gekko’s estimate Bausch Health Companies is undervalued: the Oct 12, 2026 close of $5.93 is 39.1% below Gekko Fair Value of $9.73. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Bausch Health Companies report earnings next?
Bausch Health Companies is expected to report on Oct 28, 2026 (16 days away). Analysts expect earnings of $1.25 per share on revenue of $2.72B. Bausch Health Companies beat the earnings estimate in 4 of its last 8 reports, moving 7.3% on average across the report.
What is Bausch Health Companies’s 52-week high and low?
Bausch Health Companies’s 52-week high is $8.00 and its 52-week low is $4.33; it closed at $5.93 on Oct 12, 2026, −7.2% over the past year. Over the last five years the shares peaked at $29.31 on Oct 25, 2021.
Is Bausch Health Companies stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 2 of the 5 items with data read as supportive (fair value and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (earnings risk). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Bausch Health Companies the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.